Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
NCT04084678 · United Therapeutics · PHASE3 · terminated · last registry update 2026-07-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, United Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGIR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-06Phase 3 first posted: United Therapeutics, treprostinil SMI (treprostinil inhalation spray) (NCT07923526)
- 2026-10-15Results posted on the registry: United Therapeutics, Placebo + Inhaled Treprostinil (NCT05255991)
- 2026-09-04Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07805785)
- 2026-07-20Results posted on the registry: Actelion, Selexipag + Placebo (NCT04175600)
- 2026-05-27Also stopped (terminated): United Therapeutics, Inhaled treprostinil solution (NCT03794583)
- 2026-03-27Phase 3 first posted: University Hospital, Rouen, Iloprost + Placebo (NCT07498309)
- 2026-03-19Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07481981)
- 2025-12-16Phase 3 first posted: Liquidia Technologies, Inc., L606 + Placebo (NCT07285655)
- 2025-12-03Results posted on the registry: Mayo Clinic, Treprostinil (NCT05564637)
- 2025-11-18Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07234032)
- 2025-09-17Phase 3 first posted: Insmed Incorporated, Treprostinil Palmitil Inhalation Powder + Placebo (NCT07179380)
- 2025-07-31Results posted on the registry: Aerogen Pharma Limited, VentaProst (NCT03122730)
- 2025-07-31Results posted on the registry: Aerogen Pharma Limited, VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (NCT04452669)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision